Project Title

A Phase 3 Study to evaluate the safety and efficacy of Efgartigimod PH20 subcutaneous in adult patients with primary immune thrombocytopenia (ADVANCE SC+)

Official Title

A Phase 3, Multicenter, Open-Label, Long-Term Trial to evaluate the safety and efficacy of Efgartigimod (ARGX-113) PH20 subcutaneous in adult patients with primary immune thrombocytopenia

Project Summary

A Phase 3 study to evaluate the safety and efficacy of efgartigimod PH20 subcutaneous in adult patients with primary immune thrombocytopenia

Blood Disorder

• Primary immune thrombocytopenia

Patient Recruitment Details

Patient recruitment status: closed

Number of patients (Globally)

Undetermined.